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Abstract
The principal targets for anti-chemokine therapy in inflammatory bowel disease (IBD) have been the 
receptors CCR9 and CXCR3 and their respective ligands CCL25 and CXCL10. More recently CCR6 
and its ligand CCL20 have also received attention, the expression of the latter in enterocytes being 
manipulated through Smad7 signalling. These pathways, selected based on their fundamental role 
in regulating mucosal immunity, have led to the development of several therapeutic candidates 
that have been tested in early phase clinical trials with variable clinical efficacy. In this article, 
we appraise the status of chemokine-directed therapy in IBD, review recent developments, and 
nominate future areas for therapeutic focus.
Key Words:  Eldelumab, Mongersen, Vercirnon
1. Introduction
Effective immune surveillance involves the continuous patrolling of 
tissues by leukocytes able to respond to foreign antigens and thereby 
mount protective immune responses. This process is dependent 
upon the ability of leukocytes to reach tissues via the blood and 
then traverse vascular beds in response to local signals presented 
by endothelial cells. An initial capture step, classically mediated 
by selectins, brings a leukocyte flowing in the blood into contact 
with endothelium.1 This induces tethering or rolling, an inherently 
unstable transition state, that is converted into firm leukocyte arrest 
by chemokine-mediated triggering of leukocyte integrins to bind 
immunoglobulin superfamily members. Once stable adhesion is 
achieved, chemokines are able to provide directional migratory sig-
nals that direct leukocyte crawling within, through, and beyond the 
vasculature towards targets within tissue.
Chemokines encompass a group of small (8–12 kDa) heparin-
binding cytokines with the ability to induce leukocyte migration.2 
Virtually any cell type can express and secrete chemokines upon 
stimulation, including endothelial, epithelial, and stromal cells as 
well as leukocytes. Chemokines can operate as a soluble gradient 
to induce chemotaxis or after being immobilised on, for instance, 
the endothelial glycocalyx via glycosaminoglycan binding or within 
the extracellular matrix. This process allows multiple chemokines to 
be sequestered, often in multimeric forms, at sites of inflammation 
and prevents them from being ‘washed away’, facilitates chemokine 
localisation by leukocytes, and increases their affinity toward cog-
nate receptors.3 Immobilised chemokines can also persist at higher 
local concentrations than the freely diffusible state,2 while enhanc-
ing the function of one another in a phenomenon referred to as 
chemokine cooperativity.4
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Classification of chemokines can be based on structure and the 
position of conserved cysteine residues (Table 1), or functionally as 
to whether they play a role predominantly in the context of inflam-
mation, or constitutively expressed under homeostatic conditions. 
Inflammatory chemokines are released by a wide range of cell types 
in response to pro-inflammatory cytokines, tissue injury, or contact 
with pathogens. Such chemokines are secreted early in response to 
pathogen recognition receptor activation on epithelial, stromal, and 
immune cells,2 to recruit the first wave of innate immune effectors 
including neutrophils, monocytes, natural killer (NK cells), and NKT 
cells. Chemokines also promote the migration of activated dendritic 
cells (DC) into secondary lymphoid tissues to activate adaptive 
immunity and the recruitment of T effectors (Teff) to the site of injury. 
Regulatory T cells (Treg) are recruited in a similar manner, and the 
balance between effector and regulatory cell recruitment will deter-
mine the outcome of the immune response. Homeostatic chemokines 
are constitutively expressed in lymphoid and non-lymphoid tissues 
where they mediate the physiological trafficking and positioning 
of cells involved in antigen sampling and immune surveillance. 
Functional distinctions are not absolute, and chemokines previously 
thought to be homeostatic are often induced and up-regulated at 
sites of chronic inflammation.2
In the gut, different intestinal sites show distinct patterns of 
chemokine expression, which serves to compartmentalise leukocyte 
recruitment, thereby regulating regional immunity. For example, 
under non-inflammatory conditions the chemokine CCL25 is 
expressed by small intestinal but not colonic epithelium, where 
it supports the recruitment of T cells and B cells expressing its 
receptor CCR9;5 whereas CCR10 and G protein-coupled receptor 
(GPR)-15 are involved in recruiting IgA+ plasmablasts and T cells, 
respectively, to the colon.6–8 In response to inflammation however, 
other chemokines can predominate; for instance interferon-induced 
CXCL10 can recruit CXCR3-expressing effector cells to the small 
bowel.9 Conversely in active ulcerative colitis (UC), CCL25 which 
was previously believed to be involved in small bowel immune 
homeostasis becomes detectable in the human colon, with expres-
sion levels correlating with disease activity.10 These findings suggest 
that expression of chemokines shape regional differences in immune 
composition along the normal intestine and determine the nature of 
inflammation in disease.11–14
2. CCR9 and CCL25
A greater understanding of the role of chemokines in coordinating 
the development and maintenance of mucosal immunity, in addition 
to the nature of pathological inflammation in the gut, has suggested 
therapeutic strategies for targeting leukocyte recruitment pathways 
in inflammatory bowel disease (IBD).
The chemokine CCL25 and its receptor CCR9 are essential for 
optimal mucosal immune development and function, with the lat-
ter being expressed by 58–97% of lymphocytes imprinted with gut-
tropism.15–18 Activation of CCR9 by CCL25 induces pro-migratory 
responses, including the activation of α4β1 and α4β7 integrins to 
bind vascular cell adhesion molecule (VCAM)-1 and mucosal addres-
sin cell adhesion molecule (MAdCAM)-1, respectively, on mucosal 
vessels.19,20 CCR9-CCL25 interactions shape the gut lamina propria 
and the development of gut cryptopatches and the intra-epithelial 
lymphoid compartment through recruitment of CD4 and CD8 T 
cells, IgA-secreting B cells, and subsets of dendritic cells.21–26 However, 
whereas lymphocytes derived from knockout animals are hampered 
in their ability to enter the gut in competitive homing experiments,22 
Ccr9–/– mice exhibit only a mild phenotype under basal conditions 
with only modest reductions in numbers of intraepithelial lympho-
cytes (IELs),27 suggesting that T cells can enter the intestine through 
CCR9-independent as well as dependent mechanisms. This is particu-
larly the case in the context of inflammation when other pathways 
including those involving CXCR3 play a more dominant role.9
The only known ligand for CCR9 is CCL25, expression of which 
is largely restricted to thymic and small bowel epithelium under nor-
mal conditions, although in response to inflammation, CCL25 is also 
detected in the colon and liver.10,28 Early growth response protein 
(EGR)-1 and caudal-related homeobox transcription factor (CDX) 
have been reported to increase CCL25 transcription in endothe-
lial cells, but the role of conventional inflammatory stimuli such as 
tumour necrosis factor alpha (TNFα) or interferon (IFN)-γ remain 
controversial.11,17 Murine studies report a gradient of CCL25 expres-
sion throughout the normal gut, with highest tissue levels detected 
proximally in the duodenum and lowest in the ileum and very lit-
tle if any detected in the non-inflamed colon.22 Furthermore, there 
appears to be differential dependence on CCR9 and CCL25 for 
recruitment to the lamina propria (LP) and the intestinal epithelium 
dependent (in part) on cell type.9,15
Table 1. Chemokine-mediated recruitment in the small bowel and colon.
Site Constitutively expressed Increased in response to inflammation
Small bowel CCR6 – CCL20
CCR9 – CCL25
CCR10 – CCL28
CXCR1 – CXCL5/6/8
CXCR2 – CXCL1/2/5/6
CXCR6 – CXCL16
CX3CR1 – CX3CL1
α4β7 – MAdCAM-1 (increased)
VAP-1
α4β1 – VCAM-1αLβ2 – ICAM-1
CCR2 – CCL2/7/8
CCR6 – CCL20
CCR5 – CCL3/4/5/8
CXCR3 – CXCL9/10/11
CX3CR1 – CX3CL1 (increased)
Colon CCR5 – CCL3/4/5/8
CCR6 – CCL20
CCR10 – CCL28
CX3CR1 – CX3CL1
CCR2–CCL2/7/8
CCR3 – CCL11 (UC)
CCR4 – CCL17 (murine colitis)
CCR6 – CCL20
CCR9 – CCL25 (UC)
CXCR1 – CXCL5/6/8
CXCR2 – CXCL1/2/5/6
CXCR3 – CXCL9/10/11
UC, ulcerative colitis.
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Studies of the CCR9-CCL25 axis in IBD have given differ-
ent results depending on the model studied and the time course of 
inflammation. Neutralising antibodies to CCL25 reduced the adhe-
sion of adoptively transferred intestinal lamina propria lymphocytes 
(LPL) and intraepithelial lymphocytes (IEL) to TNF-activated small 
intestinal post-capillary venules, but not to colonic vessels.17 In the 
SAMP1/YitFc model of murine ileitis, a significantly greater pro-
portion of CD4+ and CD8+ lymphocytes are CCR9+ compared with 
wild-types, and histological indices of early but not late intestinal 
inflammation are lessened following administration of antibodies 
targeting the CCR9-CCL25 axis.29 The ileitis seen in Rag2-deficient 
mice is also attenuated in the absence of CCR9, although these 
findings conflict with the TnfΔARE model of IBD, wherein CCR9 
deficiency is associated with a reduction in gut Treg and persistent 
intestinal inflammation.30–32 Consistent with the latter, CCR9 can 
be expressed by subsets of Treg and immunosuppressive DC popu-
lations.25,30,31,33 Indeed, following adoptive transfer of CD4+ T-cells, 
Ccr9-/- Rag2-/- mice develop small bowel inflammation, suggesting 
that non-T cell CCR9+ populations are partially responsible for 
maintaining tolerance in this model. Furthering the argument for 
an immune modulatory role of CCR9 cells, Wurbel et al. reported 
that CCR9-CCL25 interactions are critical for protective responses 
against large intestinal inflammation in acute and chronic models of 
dextran sulphate sodium (DSS)-induced colitis.34,35
There are several potential explanations for these different find-
ings. Imprinting of CCR9 is retinoic acid dependent, and in the 
presence of transforming growth factor (TGF)-β is associated with 
induction of FoxP3. Indeed, CD4+ Treg preferentially express CCR9 
when compared with effector counterparts in the TnfΔARE model, 
and CCR9+ CD8+ subsets can inhibit of proliferation of CD4+ 
T-cells in vitro. Wermers et  al. report highly concordant expres-
sion of CCR9, FoxP3, and CD103 in mice, suggesting that CCR9 is 
required for T cell-mediated regulation of chronic ileitis.30 Moreover, 
CCR9-CCL25 interactions are critical for establishing early thymo-
cyte colonisation and selective maturation of T cells that are tolerant 
to self-antigens (hence the synonym for CCL25: thymic expressed 
chemokine; TECK).26 However, clinical studies illustrate increased 
numbers of CCR9+ T cells in blood from individuals with small 
bowel inflammation;36 and CCR9+ T cells isolated from mesenteric 
lymph nodes (MLN) of patients with Crohn’s disease are more acti-
vated and show enhanced IFN-γ and interleukin (IL)-17 secretion 
when compared with lymphocytes extracted from normal MLN.36,37
Collectively, these findings imply that although congenital ab-
sence has potentially harmful consequences, targeted therapy against 
CCR9 or CCL25 may be beneficial in the prevention or treatment 
of small bowel inflammation. This hypothesis is supported by clin-
ical trial data in which clinical and endoscopic indicators of small-
intestinal Crohn’s disease improved following treatment with the 
CCR9-antagonist Vercirnon.38
Whereas a role for lymphocyte CCR9 is accepted in the small 
bowel, controversy has existed over the roles of CCR9 and CCL25 
in the colon.37,39 Murine studies suggest that under non-inflamma-
tory conditions, Ccl25 gene expression is restricted to the small in-
testine in uninjured wild-type mice9,24,40 and that is also the case in 
some IBD models, including the Samp1/YitFc model of ileitis,29 the 
TnfΔARE model of small bowel Crohn’s disease,30 and spontaneous 
ileitis in Rag2-/- mice.31 Studies in pigs again suggest differential ex-
pression along the small intestine which is dependent on the micro-
biota.41 Nevertheless, colonic CCL25 transcripts have been reported 
in spontaneous murine models of colitis,42 as well as colonic inflam-
mation induced by dextran sulphate sodium34,35 and oxazolone.43
In humans there has been even more variability in findings. In 
some studies, fewer than 10% of cultured T cells isolated from 
colonic lymphoid tissue expressed CCR9 irrespective of inflam-
matory status, and lower frequencies of circulating CD4+ T cells 
expressed CCR9 in patients with colonic versus small bowel Crohn’s 
disease.39 Consistent with this, northern blotting was able to detect 
CCR9 mRNA in small bowel but not colonic tissue.16 In other stud-
ies, increased CCR9 expression gauged by median fluorescence 
intensity (MFI) has been reported on subsets of CD3+ T cells and 
CD14+ monocytes in the blood of a small number of UC patients.44,45 
IL-17+ CCR9+ γΔ T cells have also been implicated in the mediation 
of extraintestinal inflammation in humans, and are increased in 
the blood of patients with active UC.46,47 Recent studies from our 
group and others have extended upon these observations, to confirm 
elevated serum levels of CCL25 in patients with UC48 and, most sig-
nificantly, a strong positive correlation between CCL25 gene expres-
sion in the colonic mucosa and both the Mayo endoscopic sub-score 
and mucosal TNFα levels in ulcerative colitis patients.10 This was 
validated by CCL25 protein expression in the inflamed colon and a 
high frequency of CCR9+ colon-infiltrating effector T cells.10,42 Such 
findings may contribute to the increased colonic cancer risk in colitis 
which relates to inflammatory burden, given the ability of CCR9-
CCL25 interactions to mediate colonic tumour growth, invasion, 
and metastasis.49
2.1. Therapeutic targeting of CCR9/CCL25
The biological role of the CCR9-CCL25 axis and the evidence impli-
cating CCR9, and CCL25 in gut inflammation in both human and 
murine IBD, suggest this is an appropriate pathway to target thera-
peutically.10,29,39,50,51 However, the involvement of CCR9 and CCL25 
in immune regulation and tolerance raises valid concerns that under 
some circumstances inhibition could be detrimental. Studies of immu-
noblockade of CCR9 and CCL25 in the Samp1/Yit model, showing 
an effect on early but not late inflammation, suggest that timing of 
intervention may also be important, with the possibility of a role in 
preventing or inducing rather than maintaining remission.29 The only 
orally bioavailable CCR9 antagonist, CCX282-B (Chemocentryx, 
USA)52 is a potent inhibitor of CCR9+ T cell-mediated chemotaxis 
in vitro, and results in near complete protection against ileitis in 
the TnfΔARE model.34 Additionally CCX282-B attenuated colitis in 
oxazolone-treated animals.43
The encouraging results from preclinical models have thus led 
to clinical study in IBD. The PROTECT-1 phase IIb trial randomly 
allocated patients with Crohn’s disease to placebo or one of three 
treatment dosages, organised into: an induction phase (induction of 
clinical response at Weeks 8 and 12); an active, open-label study 
phase (4 weeks) in which all eligible participants received CCX282-B 
at 250 mg twice daily; and a maintenance period in which patients 
who showed clinical response during the active phase were re-ran-
domised to receive placebo or CCX282-B at a dose of 250 mg twice 
daily. The induction phase of PROTECT-1 failed to attain its pri-
mary endpoint of a significant reduction in the CD Activity Index 
(CDAI) of 70 points at Week 8 of treatment, although a greater 
number of patients on the 500  mg daily dose regimen achieved 
clinical response compared with placebo (Table 2). The fact that re-
sponse rates were similar between placebo and the 250 mg treatment 
groups suggests this dose may be suboptimal, although 41% of sub-
jects on CCX282-B were in corticosteroid-free remission compared 
with 28% on placebo (P  = 0.041). The active treatment phase of 
PROTECT-I gave all patients an opportunity to receive active treat-
ment, following which patients who showed a clinical response were 
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re-randomised to receive placebo or CCX282-B (250 mg twice daily) 
as maintenance therapy. Remission was achieved in 47% of patients 
on CCX282-B treatment compared with 31% of those on placebo 
(P = 0.012), together with a reduction in median overall CDAI.
Following the results of the phase IIb study, CCX282-B was 
reformulated and renamed (initially GSK1605786 Formulation A, 
and later Vercirnon) and studied in a phase III double-blind ran-
domised placebo-controlled trial. SHIELD-1 was conducted over 
162 centres in 23 countries between 2010 and 2013, and included 
patients with a CDAI of 220–450, evidence of active Crohn’s disease 
endoscopically, or with elevated inflammatory markers, and if they 
had failed corticosteroid or immunosuppressive therapy.54 No sig-
nificant difference in remission rates (defined as a reduction in CDAI 
of ≥ 100 points by Week 12) was observed between either of the 
treatment arms compared with placebo (Table 2).
The reasons for the discrepancy in outcome between the Phase IIb 
PROTECT-1 study and the Phase III SHIELD-1 study are unclear but 
could reflect differences in the patients recruited; previous anti-TNFα 
treatment was reported in 69% of patients comprising SHIELD-1 
versus 26% in PROTECT-1. Another plausible reason for failure in 
the phase III Vercirnon study may stem from differences in clinical 
trial design. For instance, PROTECT-I comprised a 12-week placebo-
controlled lead-in followed by 4 weeks of open-label treatment.
It is also possible that 12 weeks is insufficient time for the drug 
to deplete the lamina propria of effector populations, because pre-
viously recruited cells may be retained for several weeks before 
they die in situ. This would be consistent with the positive effects 
on maintenance of remission reported in PROTECT-1.51 Although 
results from the maintenance phase of the SHIELD programme have 
not been published, the aim of SHIELD-4—a randomised double-
blind induction study for patients with moderate-to-severe Crohn’s 
disease—was to treat patients with one of two dose regimens of 
Vercirnon, and enrol clinical responders to a Phase III maintenance 
clinical trial (SHIELD-2).55 The primary endpoint of the trial was the 
proportion of patients with a Crohn’s disease activity index (CDAI) 
≥ 100-point response (100-point decrease in CDAI score) at Week 
12. The secondary endpoint was the proportion of patients in clin-
ical remission (CDAI < 150) at Week 12. Adult patients with a base-
line CDAI of 220 to 450, C-reactive protein (CRP) ≥ 3 mg/L or faecal 
calprotectin > 200 μg/g were randomised to receive either 500 mg 
four times daily (q.d.s.) or 500 mg twice daily (b.d.) Vercirnon for 
12 weeks. Baseline CDAI was 323 (± 56) with a range of 220–450. 
In those who completed the trial before premature study termination 
(n = 118), the CDAI ≥ 100-point response at Week 12 was 56% and 
69% in the 500-mg q.d.s. and in the 500-mg b.d. groups, respect-
ively, similar to the PROTECT-1 data. Within the same observed 
population, rates of remission (defined as CDAI < 150) at Week 12, 
were 26% and 36%, respectively. To the authors’ knowledge, no fur-
ther data relating to the SHIELD-2 maintenance study are available.
The failure to reach primary endpoints in the phase III clinical 
trial has delayed further development of anti-CCR9 therapy in IBD. 
However, pre-specified subgroup analysis in SHIELD-1 did show a 
higher clinical response for Vercirnon treatment compared with pla-
cebo, specifically in patients with colonic disease: CDAI response at 
Week 12 of 25.4%, 28.8%, and 13% in the once daily, twice daily, 
and placebo groups, respectively.57 Although the investigators state 
a lower placebo response rate as one factor that could explain this 
observation, it is also possible that this was a real effect consistent 
with the fact that CCR9+ T cell frequencies do not correlate with 
inflammatory activity in the small bowel, whereas they correlate 
strongly with disease activity in the colon.10 The current evidence 
therefore indicates that a randomised placebo-controlled trial of 
Vercirnon, specifically for patients with ulcerative colitis, is justified.
In addition to circulating gut homing T cells, subsets of pro-
inflammatory monocytes also express high levels of CCR9,44 and their 
frequencies in the circulation correlate with clinical activity in some 
IBD patients. A recently published study reports the successful treat-
ment of a patient with refractory UC, by depleting CCR9 cells from 
the blood using leukapheresis. Clinical and endoscopic remission was 
associated with a greater reduction in CCR9 expression on circulat-
ing T cells and monocytes.45 This led to a subsequent double-blind 
placebo-controlled trial of leukapheresis to deplete CCR9+ monocytes 
in ulcerative colitis, which was associated with improvement in the 
endoscopic Mayo score compared with placebo (Table 2).56
3. CXCR3 and CXCL10
CCL25 and CCR9 drive gut specific leukocyte recruitment under 
homeostatic and inflammatory conditions, but in the context of IBD 
their role can be overshadowed by inflammatory chemokines.11,12 
Human LPL and IEL express the chemokine receptors CCR2, 
CCR5, and CXCR3 that play an important role during leukocyte 
recruitment to the inflamed intestine.11 Under normal circumstances 
the colonic epithelium expresses low levels of the chemokine ligands 
for CXCR3 (namely CXCL9, CXCL10, and CXCL11). However, 
the expression of one of these, CXCL10, which is an IFN-γ inducible 
chemokine, increases markedly in colitis.57,58 CXCR3 is expressed 
at high levels on tissue-infiltrating, activated T cells in a num-
ber of inflammatory disorders, and mucosal biopsies taken from 
patients with active UC and Crohn’s disease demonstrate increased 
frequencies of CXCR3+ cells associated with strong expression of 
CXCL10.59–61 Of note, the latter has been implicated in the induc-
tion of Th1 responses across inductive sites such as MLNs, as well 
as the promotion of effector cell recruitment to inflamed gut tis-
sue. Zhao et al. have also demonstrated that the CXCL10/CXCR3 
axis mediates monocyte activation and drives tissue inflammation 
by innate immunity distinct from the conventional paradigm as a 
regulator of immune cell recruitment.62 In contrast to CXCL9 and 
CXCL11, CXCL10 alone was necessary and sufficient for IFN-γ 
primed monocytes to promote pro-inflammatory cytokine release, 
indicating a non-redundant role of CXCL10 in inflammation. 
Moreover, CXCL10 signalling was able to synergise with lipopoly-
saccharide to potentiate much greater amounts IL-12 and IL-23 
release by monocytes.
A therapeutic role targeting CXCR3 is supported by studies in 
the Il-10–/– model of IBD. Frequencies of CXCR3+ cells increase in 
mesenteric lymph nodes and Peyer’s patches associated with Th1-
mediated injury, and inhibition of CXCL10 attenuates the rate and 
intensity of colitis and intestinal inflammation.63,64 CXCR3-deficient 
mice also develop a much milder colitis in response to dextran sul-
phate sodium. This is associated not only with reduced inflamma-
tion but also changes in epithelial cell proliferation, suggesting direct 
effects of CXCR3 chemokines on epithelial cells in the gut.65,66
3.1. Clinical trials targeting CXCR3/CXCL10
Eldelumab (BMS-936557, previously named MDX-110067) is a fully 
human monoclonal antibody to CXCL10 which has been investi-
gated for the treatment of moderate to severe UC in a phase IIa mul-
ticentre, double-blind randomised placebo-controlled trial.68 Despite 
a trend toward increased clinical response at Day 57, as evidenced 
by clinical remission and mucosal healing, there were no significant 
differences in the primary or secondary endpoints between treatment 
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versus placebo groups (Table 3). However, the study yielded a nota-
ble exposure-response relationship, with Eldelumab clinical response 
and mucosal healing rates being greatest in patients with the high-
est trough concentrations.68 We have observed similar outcomes 
in a trial of NI-0801, a monoclonal antibody against CXCL10, in 
patients with the immune-mediated liver disease primary biliary 
cholangitis (PBC), which suggests that the high production rate of 
CXCL10 by inflamed tissues makes it difficult to achieve therapeutic 
drug levels and sustained neutralisation of the chemokine in vivo 
(K. de Graaf et al; submitted).
Based on the phase IIa data, a 100-µg/mL trough value was 
considered the ‘target for efficacy’ in a phase IIb dose-ranging in-
duction study in UC (Table 3).69 The proportion of patients achiev-
ing clinical remission by Week 11 (primary endpoint) was no 
different between placebo versus either the Eldelumab 15  mg/kg 
or the Eldelumab 25 mg/kg group. This was despite 79% and 97% 
of patients in the treatment groups maintaining a trough plasma 
concentration of 100 µg/mL, respectively. Although a numerically 
higher proportion of patients in the Eldelumab treatment arms 
achieved clinical response, rates of mucosal healing were similar 
when compared with placebo. In subgroup analysis, greater efficacy 
was observed in Eldelumab-treated patients who were anti-TNFα 
naïve,69 and for the 25 mg/kg subgroup who were receiving concur-
rent immunomodulators.
Results from a phase IIa trial in Crohn’s disease were also 
recently published.70 The primary objective was to demonstrate 
dose response; no exposure-remission relationship was seen with 
Eldelumab, although a trend towards clinical and endoscopic effi-
cacy was observed. There was no statistically significant relation-
ship between trough drug levels and clinical remission by Week 11, 
suggesting that at the doses of 10 and 20 mg/kg studied, clinical 
efficacy had been maximised.70 Moreover, there were no significant 
Table 3. Clinical trials targeting CXCR3/CXCL10 in IBD.
Compound Entry criteria Cohort size and 
organisation
Primary endpoint Potential expedients
A) Phase IIa68
BMS-936557 (IV) Inclusion: 
UC; active flare despite 5-ASA or 
immunosuppressiona
- Mayo score 6–10
- Mayo endoscopic sub-score ≥ 2
Exclusion: 
- Fulminant UC
-  Anti-TNFα therapy in preceding  
8 w
- Placebo (n = 54)
-  BMS-936557  
10 mg/kg (n = 55)
Induction period; 
8 w
Dec. in Mayo score ≥ 3 at 
57 d + dec. in rectal bleed 
score ≥ 1 or absolute bleed 
score ≤ 1
- Placebo 35%
- 10 mg/kg: 53%
P = 0.083
Attaining primary endpoint by dose-
response (drug trough drug values)
- Placebo: 37%
- 26–79 µg/mL: 53%
- 79–105 µg/mL: 63%
- 108–235 µg/mL: 88%
Mucosal healing
- Placebo: 35%
- 26–79 µg/mL: 29%
- 79–105 µg/mL: 44%
- 108–235 µg/mL: 69%
B) Phase IIb69
BMS-936557 (IV)
- Eldelumab
Inclusion: 
UC; moderate to severe activitya
- Mayo score ≥ 6
- Mayo endoscopic subscore ≥ 2
-  Inadequate response to  
existing medical therapy; any type
Exclusion:
- As above
- Placebo (n = 83)
-  Eldelumab 15  
mg/kg (n = 84)
-  Eldelumab 25  
mg/kg (n = 85)
Induction period; 
11 w
Mayo score < 2 by 11 w + 
no individual component 
> 1
- Placebo: 9.6% vs
- 15 mg/kg: 13.1%; 
P = 0.515)
- 25 mg/kg: 17.6%; 
P = 0.158)
Subgroup analysis of primary 
endpoint and mucosal healing greater 
compared with placebo in: 
(A) anti-TNFα naïve; and 
(B)  immunomodulator-exposed  
subgroups
C) Phase IIa70
BMS-936557 (IV)
- Eldelumab
Inclusion: 
Moderate to severe Crohn’s disease
- CDAI 220 to 450
- CRP ≥ 5 mg/L, or
- Faecal calprotectin > 250 µg/g, or
- SES-CD of 2 to 3
-  Insufficient response/intolerance  
to prednisolone (≥ 40 mg/d 
for 2 w (or equivalent) or 
immunomodulators 
Exclusion: 
-  Penetrating disease or fibrotic  
stenosis
- Surgery within 6 m of screening
-  Anti-TNFα therapy in preceding  
8 w
- Placebo (n = 40)
-  Eldelumab  
10 mg/kg (n = 40)
-  Eldelumab  
20 mg/kg (n = 41)
1) Steady-state plasma 
concentration for induction
-  No statistically significant 
exposure-remission 
relationship with 
Eldelumab at 11 w
OR: 1.06 (90% CI 
0.96–1.18)
2) Efficacy: CDAI < 150 by 
11 w; treatment differences
- 10 mg/kg vs placebo: 9%
- 20 mg/kg vs placebo: 13%
Composite endpoint analysis showed 
increased response rate for both doses 
vs placebo
5-ASA, 5-aminosalicylic acid; CDAI, Crohn’s Disease Activity Index; CI, confidence interval; d, day; dec., decrease; IV, intravenous; m, month; SES-CD, simpli-
fied endoscopic score of Crohn’s disease; TNF, tumour necrosis factor; OR, odds ratio; UC, ulcerative colitis; w, week, IBD, inflammatory bowel disease; CRP, 
C-reactive protein.
a2 w before drug administration and of ≥ 6 m duration.
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differences in the rate of remission or CDAI response rates between 
either the 10 mg/kg or 20 mg/kg treatment groups versus placebo 
(Table 3). As with previous clinical trials in IBD, clinical response 
was more pronounced for treatment subgroups who were anti-TNFα 
naïve or receiving concurrent immunomodulatory treatment.70
This was one of the first placebo-controlled, prospective stud-
ies with central endoscopy reading for patients with moderate to 
severe Crohn’s disease. This follows lessons from the earlier UC trial 
of Eldelumab as well as others, in which high but variable muco-
sal response rates were seen with placebo.69 Treatment with both 
Eldelumab doses resulted in mean reductions in the endoscopic degree 
of inflammatory activity measured by the simplified endoscopic score 
in Crohn’s disease (SES-CD): 3.44, –3.57, and –0.94, for 10 mg/kg, 
20  mg/kg, and placebo groups, respectively).70 Unlike with clinical 
response, endoscopic activity following Eldelumab did not differ in 
those patients with previous exposure to biologic therapy,70 neither did 
this vary according to baseline severity of endoscopic disease. Although 
the trial was not powered to test efficacy endpoints, given the lack of 
agreement between clinical and endoscopic findings a composite post 
hoc endpoint analysis was conducted. Therein, response was deter-
mined if ≥ 30% improvement in clinical symptoms occurred together 
with either: (i) a 3-point decrease in SES-CD score; or (ii) an absolute 
SES-CD score of zero. This did show significant treatment differences 
between Eldelumab and placebo for both the biologic naïve and bio-
logic failure subgroups, albeit with very low placebo response rates.
The above studies all indicate that inhibition of the CXCR3-
CXCL10 pathway appears to be safe but fails to demonstrate over-
all efficacy. However, the suggestion of responses in specific patient 
populations are encouraging. It is possible that IBD results in the 
activation of several inflammatory pathways and thus inhibition of 
CXCR3 alone is insufficient to induce clinical responses. However 
further attempts to define patients based on clinical or endoscopic 
features, or perhaps more pertinent immunophenotypes, might 
allow treatment to be targeted to patient subgroups more likely to 
experience therapeutic benefit.
4. CCR6 and CCL20
The ability of intestinal epithelial cells to secrete cytokines and 
chemokines in response to commensal bacteria, pathogens, or injury 
allows them to play an active role in shaping the nature of the local 
immune response.71 IL-17-secreting innate lymphoid cells and Th17 
CD4 T cells are abundant in the gut, and the epithelium-secreted 
chemokine CCL20 plays a major part in attracting IL-17-secreting 
cells that express its sole receptor CCR6.72 Although CCL20 is 
secreted by the epithelium in response to inflammation, it is also 
constitutively expressed by the follicle-associated epithelium overly-
ing Peyer’s patches and isolated lymphoid follicles through which it 
contributes to the homeostatic development and maintenance of the 
mucosal immune system. In Ccr6 knockout mice, there is a failure 
of full development of mucosal inductive sites leading to decreased 
IgA production to oral antigens. Thus, CCL20 functions as both an 
inflammatory and a homeostatic chemokine.73
Following epithelial damage, infection, or changes in the micro-
biota, there is a shift in local mucosal immune responses away 
from regulation and towards pro-inflammatory Type-1 or Type-17 
responses, driven in part by increased production of CCL20 from 
inflamed epithelium.12,74–78 A role for CCL20 in IBD pathogenesis is 
also supported by the findings of genome association and gene expres-
sion studies,79,80 and the fact that intestinal CCL20 mRNA expression 
is up-regulated several-fold during active inflammation,77,78 enhanced 
through stimulation of toll-like receptor (TLR)-1 and TLR3.77,81 
Murine models have also shown that Th17-cells can be actively redi-
rected from the blood to the small bowel in response to CCL20,82 
and several studies report that IL-17A in turn up-regulates CCL20 
release from the intestinal epithelium, resulting in a positive feedback 
circuit that drives ongoing inflammation.82 Furthermore, neutralisa-
tion of CCL20 reduces T cell recruitment and attenuates colitis in the 
2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced murine model.83
Persistent intestinal inflammation requires not only local pro-
inflammatory signals such as TNFα that induces CCL20 secretion 
Table 4. Summary data from the Mongersen Phase II clinical trial in Crohn’s disease (orally administered).
Phase II92
Entry criteria Cohort size and organisation Primary endpoint Additional expedients
Inclusion:
-  Moderate to severe Crohn’s disease (CDAI 
220400)
-  Disease located to the terminal ileum of 
right colon
- Steroid-dependent / refractory disease
Exclusion:
-  Disease affecting the upper GI tract, 
proximal small intestine, transverse colon, 
or left colon.
-  Stricturing disease
- Penetrating disease
- Extraintestinal disease
- Anti-TNFα therapy in preceding 90 da
- Placebo (n = 42)
-  Mongersen 10 mg  
(n = 41)
-  Mongersen 40 mg  
(n = 40)
-  Mongersen 160 mg  
(n = 43)
Daily treatment for 2 w
-  Clinical evaluation at 15 d, 
28 d, and 84 d
CDAI < 150 at 15 d, and 
sustained until 28 d
-  Placebo: 10%
-  10 mg: 12%
-  40 mg: 55%
-  160 mg: 65%
P < 0.001 for 40 mg or 160 
mg groups vs either 10 mg or 
placebo groups
100-point CDAI response at 15d
- Placebo: 26%
-  10 mg: 22%- 40 mg: 45%- 160 
mg: 65%
P < 0.05 for 40 mg or 160 mg 
groups vs either 10 mg or placebo 
groups
100-point CDAI response at 28d
-  Placebo: 17%
- 10 mg: 37%
- 40 mg: 58%
-  160 mg: 72%
P ≤ 0.001 for 40 mg or 160 mg 
groups vs either 10 mg or placebo 
groups
P < 0.05 for 10 mg vs placebo 
groups
CDAI, Crohn’s disease activity index; d, days; TNF, tumour necrosis factor; w, weeks; GI, gastrointestinal.
aBefore the date of enrolment. However, patients with a worsening of disease (increase in CDAI ≥ 70 points) after 2 weeks into the trial were eligible for 
steroid, immunomodulator or anti-TNFα rescue.
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by epithelial cells,10 but also the presence of induced or constitutive 
defects in counter-regulatory mechanisms that allow inflammation 
to develop unchecked.84 One such mechanism involves TGF-β1, lev-
els of which are reduced in CD and UC due to increased expression 
of the intracellular protein Smad7.85 TGF-β1 activity can be restored 
in isolates of lamina propria mucosal cells by treatment with an 
anti-sense oligonucleotide to Smad7 termed Mongersen (previously 
GED0301), the administration of which attenuates colitis in the 
TNBS mouse model.86 Smad7-transgenic animals do not develop an 
IBD phenotype under normal circumstances but exhibit more severe 
colitis in response to DSS than wild-types.87 Moreover, Smad7-
overexpressing CD4+ T-cells induce severe colitis that is resistant to 
Treg-mediated rescue when transferred to immunodeficient mice.
88 
Marafini and colleagues have recently shown that CCL20 expres-
sion by colonic epithelial cells was inhibited by TGF-β1, but that 
this was overridden in epithelial cells that over-expressed Smad7.89 
Moreover, Mongersen administered directly to the luminal side of 
mucosa down-regulated Smad7 in a dose-dependent manner, which 
correlated with the reduction in colonic CCL20 expression.89
4.1. Targeting Smad7 and the impact on CCL20 
expression
In a small open-label and dose-finding Phase I study in Crohn’s dis-
ease,90,91 treatment with Mongersen was associated with a reduction 
in CDAI of > 70 points within 8 days across all three tested doses 
(40 mg, 80 mg, 160 mg; n = five participants per group). These results 
were swiftly followed by efficacy evaluation in a Phase II, multicen-
tre, double-blind, placebo-controlled trial.92 A  total of 166 active, 
steroid-dependent or steroid-resistant Crohn’s disease patients were 
assigned to receive one of three doses of Mongersen (10, 40, or 
160 mg per day) or placebo daily for 2 weeks. The primary endpoint 
was the proportion of individuals who reached clinical remission 
at Day 15 (CDAI < 150) maintained for at least 2 weeks. Patients 
receiving the highest doses of Mongersen experienced significantly 
higher rates of remission than those treated with 10 mg or placebo 
(Table 4). Moreover, at the end of follow-up on Day 84, the per-
centage of patients who entered glucocorticoid-free remission was 
significantly greater in the 160 mg group versus placebo. Colonic 
Smad7 expression and CCL20 levels were decreased in treated 
patients, and serum values were also reduced in those achieving clin-
ical response as early as Day 15 of treatment,89 suggesting that circu-
lating CCL20 may be a useful biomarker to monitor early response, 
efficacy, and dose titration.
A post hoc subgroup analysis of the Mongersen phase II data 
divided the cohort according to baseline disease duration (cut-point 
of 5 years), CDAI (cut-point of 260), and CRP level (cut-point of 
3 mg/L).93 The authors found that clinical remission rates (CDAI < 
150) at Weeks 2, 4, and 12 were significantly higher with Mongersen 
160 mg/day and 40 mg/day compared with placebo for each disease 
duration and CRP subgroup. Furthermore, the rate of remission was 
significantly greater with Mongersen 40 mg/day compared with pla-
cebo at Weeks 2, 4, and 12 in the subgroup of patients with CDAI 
≤ 260. The authors concluded that disease duration and baseline 
CRP did not appear to significantly affect drug efficacy. However, 
endoscopic indices of disease severity were not evaluated, and data 
from other trials suggest that baseline CDAI does not correlate with 
endoscopic remission.94 A phase III trial of Mongersen is ongoing, 
and these studies have also encouraged interest in direct anti-CCL20 
therapy, which is now being explored by GSK in a Phase I clinical 
trial of an anti-CCL20 antibody GSK3050002 (NCT01984047).
5. Critical Appraisal and Future Directions
Although it is clear that chemokines and their receptors are critical 
in the development of the mucosal immune system and in orches-
trating inflammatory responses to tissue injury and infection, only a 
few have been explored as targets for IBD.95 This may partly reflect 
current therapeutic focus within the field in targeting endothelial 
adhesion molecules, with agents such as vedolizumab. Additionally, 
concerns surround safety of targeting chemokine receptors in light 
of their widespread expression on a broad range of cell types.96 
For instance, a potential ligand for GPR15 (GPR15L) was recently 
characterised as being developmentally determined, only modestly 
affected by inflammation or the presence of microbiota, and consti-
tutively expression in the colon.97 These findings called into question 
Table 5. Safety and tolerability profiles of existing chemokine-directed agents.
Agent Commentary
CCX282-B (oral); 
Vercirnon
- No specific safety concerns in the Phase II study38
-  In the Phase III trial,54 gastrointestinal adverse events were observed at an increased frequency in the Vercirnon treatment 
groups: 30%, 37%, and 48% for placebo, Vercirnon once daily, and Vercirnon twice daily respectively (P < 0.001, 500 mg 
twice daily vs placebo), with the most common AEs being abdominal pain, Crohn’s disease worsening, nausea, and 
dyspepsia
BMS-936557 (IV); 
Eldelumab
Ulcerative colitis phase II study69
-  Infusion reactions occurred in 19%, 14%, and 5% in the 25 mg/kg, 15 mg/kg, and placebo groups, respectively. None with an 
acute infusion reactions exhibited anti-Eldelumab antibodies
-  Higher proportion of infectious complications in the 25 mg/kg group patients (26%) vs 15 mg/kg (17.9%) and placebo (18%) 
groups. The most common type of infection was nasopharyngitis (10.6%, 3.6%, and 3.6%, respectively)
Crohn’s disease phase II study70
-  Infusion reactions in 10% and 27% of patients receiving 10 mg/kg and 20 mg/kg arms; in three cases (all in the 20-kg arm), 
infusion reactions were considered serious
Mongersen (oral) - No serious concerns in the Phase II trial92
-  Theoretical risk of fibrotic stricturing disease, attributable to the role of TGF-β1 in collagen synthesis, extracellular matrix 
dynamics, and fibrogenesis. However, no patient developed small bowel strictures in a 6-month phase I study91
AE, adverse event.
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the therapeutic implications of targeting GPR15, given its role in 
mediating colitis in T cell-dependent murine models, and high expres-
sion levels on Th2 cells in the lamina propria of patients with UC.
7,8 
However, GPR15 is critical for regulating the migration of FoxP3 
Treg to the large intestine, and is also expressed on vascular endothe-
lium at similar levels to T cells, where it binds to thrombomodulin, is 
cytoprotective, and mediates critical angiogenic functions in vivo.98 
In a similar vein, maraviroc, which was developed as a therapy for 
HIV infection, is a safe and effective inhibitor of CCR5.99 The latter 
is also expressed at high frequencies by gut infiltrating lymphocytes 
and monocytes in IBD,100 suggesting it could be a promising target. 
However, its distribution on a broad range of leukocytes including 
activated, highly proliferative immunosuppressive Treg populations 
in the gut, suggest that inhibition may also disrupt critical regulatory 
pathways. Other potentials implicated in IBD pathogenesis include 
CCL17 and its only known receptor CCR4. CCL17 is increased in 
the inflamed mucosa of murine colitis,101,102 and CCL17-deficient 
animals are protected from colitis induced by DSS,103 although the 
ability of mice lacking CCR4+ T-cells to develop florid colitis sug-
gests contribution by CCR4+ innate effector cell types.
There is also a strong rationale to target gut-tropic chemokines 
in patients with extraintestinal manifestations of IBD. Of particu-
larly relevance is primary sclerosing cholangitis (PSC),12 a progres-
sive biliary disease that is associated with IBD in 70–80% of cases 
and which affects ~8% of patients with IBD, particularly colitis.104,105 
Under normal circumstances, expression of CCL25 and MAdCAM-1 
are absent from the liver, but in PSC both are detectable on hepatic 
endothelium28,106 and support the aberrant recruitment of α4β7+ 
CCR9+ effector lymphocytes from the gut.10,28,106 These effector cells 
can then exploit CCR6 to localise to biliary epithelium, where they 
drive injury upon reactivation within the liver.
Despite advances in our understanding, strategies that target 
chemokine receptors do provide unique challenges,96 and have not yet 
achieved the same level of efficacy as those directed toward integrins 
or endothelial adhesion molecules. Although safe and reasonably well 
tolerated in most studies (Table 5), it has proved difficult to deliver 
consistent inhibition with antibodies, which may reflect the high levels 
of chemokines secreted by inflamed tissues or their sequestration on 
the endothelial glycocalyx. Indeed, targeting of chemokine-receptor 
interactions may be less efficacious than therapies which inhibit bind-
ing of chemokines to glycosaminoglycans in vivo.107
Additional limitations, relevant to cytokine-directed therapies 
more broadly, include acceptance that therapeutic drug monitoring 
in peripheral blood may not necessarily reflect levels in mucosal tis-
sue. This was highlighted by the ATLAS study, which revealed no cor-
relation between anti-TNFα values in matched specimens of serum 
versus mucosal biopsies from patients with active IBD.108 Moreover, 
the ratio of anti-TNF to TNF in tissue was greatest in non-inflamed 
areas and lowest in the most severely afflicted regions. These observa-
tions have not been conclusively validated,109 but the ATLAS investi-
gators propose that local, progressive inflammation characterised by 
high tissue levels of TNFα serves as a ‘sink’ for anti-TNFα. It is plaus-
ible that the reason why some therapies fail in clinic is thus because 
of potency issues, wherein high levels of compound are required to 
‘draw out’ chemokines from out of tissue compartments.
In future, it will be important to look at new ways of modelling 
pharmacokinetics for such antibodies, to ensure that trials are not fail-
ing due to suboptimal dosing.52,53 Furthermore, the large numbers of 
different players secreted in the context of disease suggest a degree of 
redundancy in inflammation-induced pathways, which could potentially 
reduce the efficacy of therapy targeted at single chemokines or recep-
tors. This suggests that targeting chemokines that play a specific role in 
the gut or in the recruitment of particular, critical immune subsets may 
be more effective than targeting receptors involved more broadly during 
an inflammatory response, such as CXCR3 and CCR5. Furthermore, 
some chemokine recruitment pathways are up-regulated relatively early 
in the inflammatory process and, because most clinical trials include 
patients with active disease refractory to existing medical therapy, the 
crucial role of this pathway may have been missed. Consistent with 
this hypothesis in both the phase II and phase III anti-CCR9 trials in 
Crohn’s, clinical remission rates were greater in the group who did not 
have previous or recent exposure to biologics.38,54,69,70
It is particularly important to consider heterogeneity in the IBD phe-
notypes recruited for clinical trials, and to take in to account clinical, 
genetic, and immunophenotypic factors that might define patient sub-
sets most likely to respond. An obvious stratification in IBD is between 
Crohn’s disease and ulcerative colitis, but it may be equally important 
to take in to account the predominant site of disease, given the regional 
differences in the chemokines involved in immune cell recruitment 
between the small bowel and colon. For instance, in the small bowel 
the proportion of infiltrating CCR9+ T-cells remains relatively stable 
or may actually lessen as inflammation progresses,39 whereas in col-
itis CCL25 expression is increased in the colon and strongly correlates 
with inflammatory activity.10 The potential importance of this factor 
is emphasised by SHIELD-1 where differences between Vercirnon and 
placebo in CD were seen in patients with colitis but not small bowel 
disease.54 The Mongersen Phase II trial was considerably refined in 
light of these concerns.92 Given that the active compound is released in 
the terminal ileum and ascending colon, patients with lesions localised 
to the upper gastrointestinal tract or distal large bowel (beyond the 
transverse colon) were rightly excluded.92,93
Finally, we will increasingly use sophisticated, often unsuper-
vised, data gleaned from genomics and deep immunophenotyping, 
to determine much more precisely the immune pathways activated 
in particular patients and to use this information to target patients 
for specific therapy—for instance, patients with IL-17-dominated 
responses may respond better to therapy targeted at CCR6 or 
CCL20. Current approaches are likely to be an oversimplification, 
and detailed probing of immune pathways using novel techniques 
in patients may allow a much more nuanced approach to therapy 
selection. Herein, IBD has a real advantage over many other dis-
eases in that analysis can be carried out on the target tissue rather 
than having to be inferred from changes in blood. A  recent study 
in rheumatoid arthritis shows the potential of such approaches. 
The investigators used multidimensional cytometry and single-cell 
transcriptomics to define a new population of helper T cells in the 
joints of some patients with active disease.110 These cells were asso-
ciated with disease activity and expressed distinct combinations of 
chemokines and chemokine receptors. Thus, patients in whom these 
cells are shown to be present and activated could be targeted with 
specific combinations of anti-chemokine treatment aimed at prevent-
ing the recruitment of this specific cell type early in disease.
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